Page results
-
Today we are launching the new UCLH strategy for 2023-2027. Developed with staff, patients and key partners, the strategy sets the future direction of UCLH over the next five years.
-
This page has been written for patients who are having a course of superficial radiotherapy for a skin tumour (such as a basal cell carcinoma or squamous cell carcinoma), or some other skin condition.
-
The UCLH Maternity Voices Partnership (MVP) is a team of women and their families, commissioners and providers (midwives and doctors) working together to review and contribute to the development of local maternity care.
-
Find more information on bites, stings and animal related injuries.
-
Patient Partners are patients, carers, families and people with lived experience of a specific issue or service. UCLH is committed to involving patients, carers, and members of the public in planning, developing, delivering, and monitoring the services we provide. Involving patients and the public in decision-making is crucial to ensuring that those services are what patients want and need.
-
This page provides information about the Palliative care and symptom control team
-
This page has been written for patients who have been referred for High Dose Rate (HDR) brachytherapy to the bronchus
-
This information has been written for patients who have been referred for High Dose Rate (HDR) brachytherapy to the oesophagus (gullet).
-
This diary is intended for patients undergoing thoracic surgery as a way of involving you in your recovery before your surgery as well as after.
-
Information for patients undergoing VATS for drainage of air or fluid, pleural biopsies and talc pleurodesis.
File results
-
FOI/2022/0194 - Drug treatment for lung cancer
-
FOI/2022/0199 - Trust postal service and patient communication
-
FOI/2022/0200 - IT budget/ chatbots
-
FOI/2022/0205 - Spending on communication activities
-
FOI/2022/206 - Rates for Bonham Carter House 52-54 Gower Street
-
FOI/2022/0207 - Patient treatment with Nivolumab
-
FOI/2022/0209 - Patient tracking list or waiting lists
-
FOI/2022/0211 - Enteral feeding machine mechanical insufflator
-
FOI/2022/0212 - Clotting disorders medication
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311